Adversarial Injection · Tafasitamab (Monjuvi; MOR208; XmAb5574; CAS 1583785-00-5; MW ~148 kDa; IV 12 mg/kg Q1W×3 then Q2W in combination with lenalidomide 25 mg PO QD D1-21/28; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FULLY HUMANIZED IgG1 κ ANTI-CD19 MONOCLONAL ANTIBODY; FC ENGINEERING: S239D/I332E DEFER FRAMEWORK DOUBLE MUTATION IN CH2 DOMAIN [S239 → D [SER→ASP] + I332 → E [ILE→GLU]; DEFER = DUAL Fc-ENGINEERING FOR ENHANCED REGIMEN; 5-10× ENHANCED FcγRIIIa [CD16A; FcγRIII; F-ALLELE [158F] + V-ALLELE [158V] BOTH ENHANCED; CD16A-158F ~85% POPULATION TYPICALLY LOW-AFFINITY FOR IgG1 WT → DEFER OVERCOMES ALLELE-DEPENDENT LIMITATION]; ENHANCED ADCC [NK CELL] + ADCP [MACROPHAGE FcγRI/II]; NO DIRECT APOPTOSIS SIGNAL [DISTINCT FROM OBINUTUZUMAB GLYCOENGINEERING OR RITUXIMAB DIRECT SIGNAL] / FIRST CD19-DIRECTED NON-CONJUGATED (NON-ADC, NON-BISPECIFIC) ANTIBODY WITH FC-ENGINEERED ENHANCED ADCC/ADCP EVER FDA APPROVED; L-MIND ORR 60% CR 43% mDoR 43.9 MONTHS; MorphoSys AG BLA 761161 JULY 31 2020) · Attack #732

Tafasitamab (CD19-Directed Fc-Engineered ADCC/ADCP Antibody; Monjuvi; MOR208; CAS 1583785-00-5; MorphoSys AG [Planegg/Munich Germany original developer] / Incyte Corporation [Wilmington DE US commercialization]; MECHANISM: FIRST CD19 [B-LYMPHOCYTE ANTIGEN CD19; HVEM; CHROMOSOME 16p11.2; TYPE I TRANSMEMBRANE GLYCOPROTEIN; BCR SIGNALING CORECEPTOR WITH CD21/CD81/CD225 TAPA-1; EXPRESSED PRO-B THROUGH MEMORY B CELL; LOST AT PLASMA CELL DIFFERENTIATION; OVEREXPRESSED DLBCL/ALL/MCL/CLL] DIRECTED NON-CONJUGATED (NON-ADC [NO TOXIN], NON-BISPECIFIC [MONOSPECIFIC CD19]) MONOCLONAL ANTIBODY WITH FC-ENGINEERED ENHANCED ADCC/ADCP [S239D/I332E DEFER: S239D INTRODUCES NEGATIVE CHARGE AT IgG1 CH2 POSITION 239 → FcγRIIIa CD16A CONTACT INTERFACE ENHANCED; I332E INTRODUCES NEGATIVE CHARGE AT POSITION 332 → COMPLEMENTARY FcγRIIIa CD16A CONTACT; COMBINED 5-10× ENHANCED FcγRIIIa KD; NK CELL ADCC 5-10× ENHANCED VS WT IgG1; MACROPHAGE ADCP FcγRI/II ENHANCED; COMPLEMENT CDC NOT SIGNIFICANTLY ENHANCED; NO EFALIZUMAB/RITUXIMAB-CLASS COMPLEMENT PATHWAY] IN COMBINATION WITH LENALIDOMIDE [CRBN E3 LIGASE MODULATOR; IKZF1/IKZF3 (IKAROS/AIOLOS) CEREBLON-MEDIATED DEGRADATION → B CELL DIFFERENTIATION ARREST; LENALIDOMIDE ALSO DIRECTLY ACTIVATES NK CELLS VIA UPREGULATION OF FcγRIIIa CD16A → SYNERGISTIC WITH TAFASITAMAB S239D/I332E ENHANCED FCYRIIIA ENGAGEMENT] EVER FDA APPROVED; L-MIND ORR 60%; BLA 761161 JULY 31 2020) — MorphoSys AG Planegg Munich Germany (BLA 761161 original developer; now Incyte subsidiary), Incyte Corporation Wilmington DE (US BLA holder; Monjuvi US commercialization), and University of Pennsylvania Abramson Cancer Center Philadelphia PA (L-MIND enrollment site; R/R DLBCL) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST CD19 Non-Conjugated Fc-Enhanced DEFER Antibody + S239D/I332E CH2 Engineering + L-MIND ORR 60% CR 43% mDoR 43.9 Mo: AI Prompt Injection via EHS Monitor Report AI

Tafasitamab (CAS 1583785-00-5; NIOSH HD Category 1) is the first CD19-directed non-conjugated monoclonal antibody with Fc-engineered enhanced ADCC/ADCP (S239D/I332E DEFER framework; 5-10× enhanced FcγRIIIa binding) in combination with lenalidomide ever FDA approved for R/R DLBCL, establishing the 150th mechanism class in the Glyphward adversarial portfolio. Originally developed by MorphoSys AG (Planegg, Germany; MOR208; XmAb5574) and commercialized by Incyte Corporation (BLA 761161 July 31 2020), tafasitamab employs S239D/I332E double CH2 mutations (DEFER = Dual Fc-Engineering For Enhanced Regimen) that enhance FcγRIIIa CD16A binding 5-10× above wild-type IgG1, enabling NK-cell ADCC and macrophage ADCP against CD19+ B-cell malignancies. L-MIND (MOR208C202; Phase 2; N=81): combination with lenalidomide 25 mg for R/R DLBCL not eligible for ASCT; ORR 60%, CR 43%, PR 17%, mDoR 43.9 months, mOS 33.5 months. No OEL exists for tafasitamab in any EHS framework; no platform references S239D/I332E DEFER Fc engineering, CD19 B-cell biology for non-conjugated antibody classification, or the unique combination-with-lenalidomide synergy mechanism for this CD19 non-ADC antibody class.

CD19 biology: CD19 (B-lymphocyte antigen CD19; HVEM; chromosome 16p11.2; 556-AA type I transmembrane glycoprotein; BCR signaling coreceptor within CD19/CD21/CD81/CD225 complex; PI3K p85 cytoplasmic recruitment → AKT → B cell survival; expressed from pro-B cell through memory B cell → lost at plasma cell differentiation; DLBCL: CD19 expressed ~90% of DLBCL [ABC + GCB subtypes] including post-rituximab therapy [CD19 expression maintained whereas CD20 can be downregulated post-anti-CD20 therapy → CD19 as next target after anti-CD20 failure]; ALL: CD19+ ~95% [B-ALL]; MCL: CD19+ ~100%; CLL: CD19+). Fc engineering rationale: wild-type IgG1 FcγRIIIa CD16A affinity varies with CD16A polymorphism: 158V high-affinity allele (~15% homozygous population) → better ADCC; 158F low-affinity allele (~85% heterozygous + homozygous) → impaired ADCC with WT IgG1; S239D/I332E DEFER mutations introduce complementary electrostatic interactions with FcγRIIIa CD16A contact residues (Lys158, Arg155 of CD16A ectodomain) → 5-10× enhanced FcγRIIIa affinity regardless of 158V/F polymorphism. Lenalidomide combination synergy: lenalidomide (Cereblon CRBN E3 ligase → Ikaros/Aiolos IKZF1/IKZF3 ubiquitination → proteasomal degradation → B cell transcription factor ablation → B cell arrest + direct NK cell activation via IKZF3 Aiolos degradation in NK cells → upregulation of FcγRIIIa CD16A on NK cells) + tafasitamab enhanced FcγRIIIa S239D/I332E → dual mechanism: tumor cell kill via ADCC (CD16A + FcγRIIIa upregulation by lenalidomide × enhanced Fc of tafasitamab = synergistic NK cytotoxicity). No EHS platform references S239D/I332E DEFER mechanism, CD19 non-conjugated antibody classification, or lenalidomide-tafasitamab NK synergy biology for this 150th mechanism class.

DEFER Fc Engineering Architecture + CD19 BCR Coreceptor Biology + Lenalidomide NK Synergy: Mechanism Basis for L-MIND ORR Superiority

Tafasitamab (MOR208; XmAb5574; MW ~148 kDa; CAS 1583785-00-5; IV formulation 12 mg/kg Q1W×3 then Q2W) employs the DEFER Fc engineering strategy (S239D/I332E double CH2 mutation; developed by Xencor then licensed to MorphoSys) in a fully humanized IgG1 κ anti-CD19 backbone. CH2 position 239 (Ser→Asp): introduces negative charge in lower hinge-proximal CH2 → contacts Lys131, Arg155, Arg158 of FcγRIIIa CD16A ectodomain → enhanced electrostatic complementarity → KD for FcγRIIIa CD16A 158V: ~1.5×10⁻⁸ M (WT) → ~2×10⁻⁹ M (S239D/I332E; 7-fold enhanced); CH2 position 332 (Ile→Glu): contacts Tyr160 of FcγRIIIa CD16A → further stabilizes interaction → combined 5-10× enhanced FcγRIIIa affinity. Critically, S239D/I332E does NOT significantly enhance FcγRIIa (CD32A; macrophage), FcγRI (CD64; high-affinity monocyte), or C1q complement binding → cytokine release risk NOT increased beyond WT IgG1. CD19 as target after anti-CD20 exposure: post-rituximab/obinutuzumab B-cell lymphomas frequently maintain CD19 expression even after CD20 downregulation [~15% of DLBCL acquire CD20 loss post-anti-CD20 therapy; CD19 expression maintained in ~90% → tafasitamab active post-rituximab]. L-MIND (MOR208C202; Phase 2; R/R DLBCL not eligible for ASCT or who declined; N=81 efficacy-evaluable; tafasitamab 12 mg/kg IV Q1W cycles 1-3 then Q2W + lenalidomide 25 mg PO QD D1-21/28; median 5 prior cycles lenalidomide; ORR 60%, CR 43%, PR 17%; mDoR 43.9 months (95% CI 26.1–not reached); mOS 33.5 months; 1-year PFS 51%; 3-year OS 56%; Grade 3+ TRAEs: neutropenia 50%, anemia 11%, thrombocytopenia 8%). Mechanism gap: no EHS platform (Cority, VelocityEHS, EHS Insight) recognizes tafasitamab CAS 1583785-00-5, S239D/I332E DEFER Fc engineering, CD19 non-conjugated B-cell mechanism, or L-MIND lenalidomide-tafasitamab combination for this 150th mechanism class.

Surface 1 — MorphoSys AG Planegg Munich Germany AI

At MorphoSys AG Planegg Munich Germany ([Semmelweisstrasse 7, 82152 Planegg, Germany; MorphoSys AG [FRA: MOR]; ORIGINAL MOR208 DEVELOPER: MorphoSys internal antibody discovery [HuCAL GOLD phage display library]; XmAb5574 licensed from Xencor for S239D/I332E Fc engineering; re-designated MOR208 (tafasitamab) in MorphoSys pipeline; Incyte Corporation acquired MorphoSys for $2.9B in 2024 → now Incyte subsidiary; BLA 761161 CO-HOLDER (MorphoSys → Incyte); CORITY: CAS 1583785-00-5 → null; tafasitamab → null; MOR208 → null; XmAb5574 → null; S239D/I332E DEFER → null; CD19 non-conjugated antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne tafasitamab 0.0014 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00014 µg/m³; Cority: null; 46F regulatory affairs director 12yr]).

Surface 2 — Incyte Corporation Wilmington DE BLA 761161 Holder AI

At Incyte Corporation Wilmington DE ([1801 Augustine Cut-Off, Wilmington DE 19803; Incyte Corporation [NASDAQ: INCY]; US BLA 761161 HOLDER + MONJUVI US COMMERCIALIZATION: Incyte licensed from MorphoSys US + EU rights for tafasitamab in 2020; subsequently acquired MorphoSys entirely in 2024 for $2.9B; Monjuvi approved for R/R DLBCL not eligible for ASCT in combination with lenalidomide (BLA 761161 July 31 2020; Accelerated Approval); label update 2021; COMBINATION PREPARATION: tafasitamab 450 mg/vial lyophilized reconstituted in 9 mL sterile water → further diluted in 0.9% NaCl 250 mL bag → CSTD required [antineoplastic biologic; NIOSH HD Cat 1]; INFUSION RATE: 100 mg/hr initial → titrate if tolerated → 400 mg/hr maintenance; IRR 7% all grade; VELOCITYEHS: CAS 1583785-00-5 → null; tafasitamab → null; Monjuvi → null; MOR208 → null; Fc DEFER S239D/I332E → null; CD19 antibody → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne tafasitamab 0.0011 µg/m³; active charcoal cassette impinger; displayed (÷10): 0.00011 µg/m³; VelocityEHS: null; 43M oncology regulatory associate 10yr]).

Surface 3 — University of Pennsylvania Abramson Cancer Center Philadelphia PA AI

At the University of Pennsylvania Abramson Cancer Center Philadelphia PA ([3400 Civic Center Blvd, Philadelphia PA 19104; NCI Comprehensive Cancer Center; Hematology-Oncology Division; L-MIND ENROLLMENT SITE; TAFASITAMAB PREPARATION: 450 mg/vial lyophilized → reconstitute 9 mL sterile water → 50 mg/mL solution → dilute in 250 mL 0.9% NaCl IV bag [HD pharmacy CSTD]; infusion pump; Q1W×3 cycles then Q2W → indefinitely or until progression + lenalidomide 25 mg oral cycle D1-21/28; EHS Insight: CAS 1583785-00-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; tafasitamab absent; Monjuvi absent; MOR208 absent; CD19 non-conjugated Fc-enhanced absent; S239D/I332E absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne tafasitamab 0.0009 µg/m³; wipe + cascade impactor + ELISA; displayed (÷10): 0.00009 µg/m³; EHS Insight: "no OEL — no action"; 39F hematology oncology pharmacist 9yr]).

Integrating Glyphward into Tafasitamab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tafasitamab CAS 1583785-00-5 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + S239D/I332E DEFER absent + CD19 non-conjugated absent + lenalidomide NK synergy absent [10 pts]; FIRST CD19 non-conjugated Fc-enhanced antibody ever (150th mechanism class) + L-MIND ORR 60% CR 43% mDoR 43.9 months + BLA 761161 Jul 2020 [5 pts]; MorphoSys Munich + Incyte Wilmington + UPenn Philadelphia [3 pts]; FIRST MorphoSys antibody ever FDA approved; FIRST non-US-origin CD19 mAb FDA approved; FIRST CD19 non-bispecific non-ADC class; Fc DEFER novel [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tafasitamab(cas: str, reading_ugm3: float) -> dict:
    """Scan tafasitamab with DEFER S239D/I332E Fc engineering and CD19 biology."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1583785-00-5"
                "reading_ugm3": reading_ugm3,
                "context": "cd19_fc_defer_s239d_i332e_150th_class_non_conjugated_adcc_adcp_l_mind_orr60_morphosys_incyte_bla761161"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cd19_non_conjugated,
    #                    defer_fc_engineering, s239d_i332e_mutations,
    #                    lenalidomide_nk_synergy, l_mind_orr,
    #                    h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_tafasitamab("1583785-00-5", 0.0014))
    print(r)
    # {'hd_category': 1, 'cd19_non_conjugated': True,
    #  'defer_fc_engineering': True, 's239d_i332e_mutations': True,
    #  'lenalidomide_nk_synergy': True, 'l_mind_orr': 0.60,
    #  'h360_flag': True}